Potential utility of BimS as a novel apoptotic therapeutic molecule

Molecular Therapy

Volumn 10, Issue 3, 2004, Pages 533-544

  Yip, Kenneth W ^a,b   Li, Anna ^a,b   Li, Jian Hua ^a,b   Shi, Wei ^a,b   Chia, Marie C ^a,b   Rashid, Shahnaz Al ^a,b   Mocanu, Joseph D ^a,b   Louie, Alexander V ^a,b   Sanchez, Otto ^a,b   Huang, Dolly ^c   Busson, Pierre ^d   Yeh, Wen Chen ^a,b   Gilbert, Ralph ^a,b   O'Sullivan, Brian ^b   Gullane, Patrick ^a,b   Liu, Fei Fei ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Adenoviridae; Apoptosis; Bim; EBV encoded nuclear antigen 1; Gene therapy; Nasopharyngeal cancer; Radiation therapy; Transcriptional targeting; Xenograft model

Indexed keywords

BIM PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; PROTEIN BCL 2; CASPASE;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; GENE INDUCTION; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER FUNCTION TEST; MITOCHONDRION; MITOSIS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN LOCALIZATION; RADIATION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ANIMAL; BIOSYNTHESIS; CELL LINE; ENZYME ACTIVATION; GAMMA RADIATION; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; NASOPHARYNX TUMOR; PROMOTER REGION; VIROLOGY; XENOGRAFT;

ADENOVIRIDAE; HUMAN HERPESVIRUS 4;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CASPASES; CELL LINE; COMBINED MODALITY THERAPY; ENZYME ACTIVATION; GAMMA RAYS; GENE THERAPY; HERPESVIRUS 4, HUMAN; HUMANS; MICE; MICROSCOPY, CONFOCAL; MITOCHONDRIA; NASOPHARYNGEAL NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSPLANTATION, HETEROLOGOUS;

EID: 4444285395     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.05.026     Document Type: Article

References (59)

1. Mendenhall W. Million R. Mancuso A. Stringer S. Management of Head and Neck Cancer-A Multidisciplinary Approach 1994 Lippincott Philadelphia
2. Yu M.C. Yuan J.M. Epidemiology of nasopharyngeal carcinoma Semin. Cancer Biol. 12 2002 421-429
3. Altun M. et al. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects Int. J. Radiat. Oncol. Biol. Phys. 32 1995 859-877
4. Lee A.W. et al. Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): report on 3-year tumor control and normal tissue toxicity Radiother. Oncol. 58 2001 121-130
5. Sultanem K. et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience Int. J. Radiat. Oncol. Biol. Phys. 48 2000 711-722
6. Lee N. et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience Int. J. Radiat. Oncol. Biol. Phys. 53 2002 12-22
7. Chow E. et al. Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study. Is combined modality treatment really necessary? Radiother. Oncol. 63 2002 269-274
8. Chan A.T. et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma Int. J. Radiat. Oncol. Biol. Phys. 33 1995 569-577
9. Al-Sarraf M. et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III Randomized Intergroup Study 0099 J. Clin. Oncol. 16 1998 1310-1317
10. Huncharek M. Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials Am. J. Clin. Oncol. 25 2002 219-223
11. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC Semin. Cancer Biol. 12 2002 431-441
12. Leight E.R. Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus Rev. Med. Virol. 10 2000 83-100
13. Li J.H. et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma Cancer Res. 62 2002 171-178
14. Li J.H. et al. Efficacy of targeted FasL in nasopharyngeal carcinoma Mol. Ther. 8 2003 964-973
15. Chia M.C. Shi W. Li J.-H. Sanchez O. Strathdee C.A. Huang D. Busson P. Klamut H.J. Liu F.-F. A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy Mol. Ther. 9 2004 804-817
16. O'Connor L. et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis EMBO J. 17 1998 384-395
17. Puthalakath H. Huang D.C. O'Reilly L.A. King S.M. Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex Mol. Cell. 3 1999 287-296
18. O'Reilly L.A. et al. The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells Am. J. Pathol. 157 2000 449-461
19. Bouillet P. Strasser A. BH3-only proteins-evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death J. Cell Sci. 115 2002 1567-1574
20. Huang D.C. Strasser A. BH3-only proteins-essential initiators of apoptotic cell death Cell 103 2000 839-842
21. Tsao S.W. Tramoutanis G. Dawson C.W. Lo A.K. Huang D.P. The significance of LMP1 expression in nasopharyngeal carcinoma Semin. Cancer Biol. 12 2002 473-487
22. Khabir A. et al. Similar BCL-X but different BCL-2 levels in the two age groups of North African nasopharyngeal carcinomas Cancer Detect. Prev. 27 2003 250-255
23. Amundson S.A. et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines Cancer Res. 60 2000 6101-6110
24. Bauerschmitz G.J. Barker S.D. Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents Int. J. Oncol. 21 2002 1161-1174
25. Palmer D.H. Mautner V. Kerr D.J. Clinical experience with adenovirus in cancer therapy Curr. Opin. Mol. Ther. 4 2002 423-434
26. Vile R. Ando D. Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider Cancer Gene Ther. 9 2002 1062-1067
27. Yamaguchi T. et al. Enhancement of thymidine kinase-mediated killing of malignant glioma by BimS, a BH3-only cell death activator Gene Ther. 10 2003 375-385
28. Naumann U. et al. Adenoviral natural born killer gene therapy for malignant glioma Hum. Gene Ther. 14 2003 1235-1246
29. Shimizu S. Tsujimoto Y. Proapoptotic BH3-only Bcl-2 family members induce cytochrome c release, but not mitochondrial membrane potential loss, and do not directly modulate voltage-dependent anion channel activity Proc. Natl. Acad. Sci. USA 97 2000 577-582
30. Li X. et al. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer Cancer Res. 61 2001 186-191
31. Kagawa S. et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax Gene Ther. 7 2000 75-79
32. Kagawa S. et al. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines Cancer Res. 60 2000 1157-1161
33. Xiang J. et al. Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer J. Gene Med. 2 2000 97-106
34. Arafat W.O. et al. An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma Int. J. Radiat. Oncol. Biol. Phys. 55 2003 1037-1050
35. Komata T. et al. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells Hum. Gene Ther. 13 2002 1015-1025
36. Xie X. et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer Cancer Res. 61 2001 6795-6804
37. Shinoura N. et al. Adenovirus-mediated transfer of caspase-8 augments cell death in gliomas: implication for gene therapy Hum. Gene Ther. 11 2000 1123-1137
38. Altieri D.C. Validating survivin as a cancer therapeutic target Nat. Rev. Cancer 3 2003 46-54
39. Reed J.C. The Survivin saga goes in vivo J. Clin. Invest. 108 2001 965-969
40. Mesri M. Wall N.R. Li J. Kim R.W. Altieri D.C. Cancer gene therapy using a survivin mutant adenovirus J. Clin. Invest. 108 2001 981-990
41. Los M. et al. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design Drug Discovery Today 8 2003 67-77
42. Reed J.C. Apoptosis-based therapies Nat. Rev. Drug. Discovery 1 2002 111-121
43. Schmitt C.A. Senescence, apoptosis and therapy-cutting the lifelines of cancer Nat. Rev. Cancer 3 2003 286-295
44. Shinoura N. et al. Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas Cancer Gene Ther. 7 2000 739-748
45. Vallera D.A. et al. Retroviral immunotoxin gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleukin-3/Bax fusion protein gene Hum. Gene Ther. 14 2003 1787-1798
46. Brewis N.D. Phelan A. Normand N. Choolun E. O'Hare P. Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis Mol. Ther. 7 2003 262-270
47. Earnshaw W.C. Martins L.M. Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis Annu. Rev. Biochem. 68 1999 383-424
48. Chen Q. Gong B. Almasan A. Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis Cell Death Differ. 7 2000 227-233
49. Scaffidi C. et al. Two CD95 (APO-1/Fas) signaling pathways EMBO J. 17 1998 1675-1687
50. Marani M. Tenev T. Hancock D. Downward J. Lemoine N.R. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis Mol. Cell. Biol. 22 2002 3577-3589
51. Liu J.W. Chandra D. Tang S.H. Chopra D. Tang D.G. Identification and characterization of Bimgamma, a novel proapoptotic BH3-only splice variant of Bim Cancer Res. 62 2002 2976-2981
52. de la Taille A. Chen M.W. Burchardt M. Chopin D.K. Buttyan R. Apoptotic conversion: evidence for exchange of genetic information between prostate cancer cells mediated by apoptosis Cancer Res. 59 1999 5461-5463
53. Fadok V.A. Henson P.M. Apoptosis: getting rid of the bodies Curr. Biol. 8 1998 R693-695
54. Mi J. Li Z.Y. Ni S. Steinwaerder D. Lieber A. Induced apoptosis supports spread of adenovirus vectors in tumors Hum. Gene Ther. 12 2001 1343-1352
55. Lax S.A. Chia M.C. Busson P. Klamut H.J. Liu F.F. Adenovirus-p53 gene therapy in human nasopharyngeal carcinoma xenografts Radiother. Oncol. 61 2001 309-312
56. Cheung S.T. et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus Int. J. Cancer 83 1999 121-126
57. Graham F.L. Prevec L. Manipulation of adenovirus vectors Murray E.J. Methods in Molecular Biology 1991 Humana Press Clifton, NJ
58. Livak K.J. Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) Method Methods 25 2001 402-408
59. Glantz S.A. Primer of Biostatistics 5th ed 2002 McGraw-Hill Toronto